Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Trial Details

NCT ID
NCT06072612
Phase
PHASE3
Sponsor
BriaCell Therapeutics Corporation
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • SV-BR-1-GM
  • Cyclophosphamide
  • Interferon infiltration of the inoculation site
  • Retifanlimab
  • Treatment of Physician's Choice
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Anaheim, California, United States|33.83529,-117.9145
  • Los Angeles, California, United States|34.05223,-118.24368
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Aventura, Florida, United States|25.95648,-80.13921

Key Eligibility Criteria

  • Be ≥ 18 years of age.
  • Have signed informed consent.
  • Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy:
  • Patients with persistent disease and local recurrence must not be amenable to local treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →